Genomics data from The Cancer Genome Atlas (TCGA) project has led to the comprehensive
molecular characterization of multiple cancer types. The large sample numbers in TCGA …

Cancer genomic, transcriptomic, and proteomic profiling has generated extensive data that
necessitate the development of tools for its analysis and dissemination. We developed …

Mass-spectrometry-based proteomic profiling of human cancers has the potential for pan-cancer
analyses to identify molecular subtypes and associated pathway features that might be …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

The heparan sulfate-degrading enzyme heparanase promotes the progression of many
cancers by driving tumor cell proliferation, metastasis and angiogenesis. Heparanase …

Both proteome and transcriptome data can help assess the relevance of non-coding somatic
mutations in cancer. Here, we combine mass spectrometry-based proteomics data with …

Therapeutic interventions that counter emerging targets in diabetes eye diseases are lacking.
We hypothesize that a combination therapy targeting inflammation and hyperglycemia can …

RNA splicing is the fundamental process that brings diversity at the transcriptome and proteome
levels. The spliceosome complex regulates minor and major processes of RNA splicing. …

Metastatic urothelial carcinoma is generally incurable with current systemic therapies. Chromatin
modifiers are frequently mutated in bladder cancer, with ARID1A-inactivating mutations …

Despite the prevalence and recognition of its detrimental impact, clinical complications of
sepsis remain a major challenge. Here, we investigated the effects of myeloid ferritin heavy …